Concizumab

Pre-clinicalActive

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Congenital Haemophilia

Conditions

Congenital Haemophilia

Trial Timeline

— → —

NCT ID

NCT04921956

About Concizumab

Concizumab is a pre-clinical stage product being developed by Novo Nordisk for Congenital Haemophilia. The current trial status is active. This product is registered under clinical trial identifier NCT04921956. Target conditions include Congenital Haemophilia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04921956	Pre-clinical	Active	—	—	Congenital Haemophilia
NCT06831734	Pre-clinical	Recruiting	May 2, 2025	Jan 31, 2031	Haemophilia A, Haemophilia B
NCT06285071	Pre-clinical	Recruiting	Aug 8, 2024	Apr 30, 2030	Haemophilia A
NCT05135559	Phase 3	Active	Mar 24, 2022	Nov 2, 2029	Haemophilia A and B With and Without Inhibitors
NCT04082429	Phase 3	Active	Nov 13, 2019	Feb 21, 2028	Haemophilia A Without Inhibitors
NCT04083781	Phase 3	Active	Oct 21, 2019	Feb 21, 2027	Haemophilia A With Inhibitors

Competing Products

20 competing products in Congenital Haemophilia

See all competitors

Product	Company	Stage	Hype Score
Tideglusib	AMO Pharma	Pre-clinical	15
Tideglusib + Placebo	AMO Pharma	Phase 2/3	57
Tideglusib	AMO Pharma	Phase 2/3	57
EDIT-101	Editas Medicine	Phase 1/2	33
Tildacerfont/Placebo	Spruce Biosciences	Phase 2	44
SPR001	Spruce Biosciences	Phase 2	44
SPR001	Spruce Biosciences	Phase 2	44
Tildacerfont/Placebo	Spruce Biosciences	Phase 2	44
Tildacerfont	Spruce Biosciences	Phase 2	44
KW-3357	Kyowa Kirin	Phase 1	33
Pasireotide 0.6Mg Solution for Injection + Saline Solution	Novartis	Phase 2	52
Sandostatine LP	Novartis	Phase 2	52
mycophenolate mofetil	Roche	Phase 1	33
turoctocog alfa + turoctocog alfa	Novo Nordisk	Phase 3	76
catridecacog + recombinant factor XIII	Novo Nordisk	Phase 1	32
activated recombinant human factor VII	Novo Nordisk	Phase 2	51
turoctocog alfa pegol	Novo Nordisk	Phase 3	76
recombinant factor XIII	Novo Nordisk	Pre-clinical	22
activated recombinant human factor VII, long acting + activated recombinant human factor VII, long acting	Novo Nordisk	Phase 1	32
Advate® + turoctocog alfa	Novo Nordisk	Phase 1	32

Other Products from Novo Nordisk

Liraglutide 3.0mg + Placebo Oral Tablet + Phentermine 15 MGApproved

Liraglutide + SalineApproved

Hydrocortisone + PlaceboApproved

biphasic insulin aspart + insulin aspartApproved

Semaglutide, 1.34 mg/mL + Empagliflozin 25 MGApproved